Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis

Masakazu Kawajiri, M. Mogi, M. Osoegawa, T. Matsuoka, K. Tsukuda, K. Kohara, M. Horiuchi, T. Miki, Jun-Ichi Kira

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We previously demonstrated that angiotensin II acts as a crucial neuroprotective factor after neural injury through angiotensin II type-2 (AT2) receptor signaling. Although the pathway is known to play an important role in the development of experimental autoimmune encephalomyelitis, cerebrospinal fluid (CSF) angiotensin II levels in patients with multiple sclerosis (MS) have never been studied. To clarify the significance of angiotensin II in MS, we assayed angiotensin II concentrations using an established enzyme-linked immunoabsorbent assay in CSF samples from patients with MS (n = 21), patients with inflammatory neuropathies (IN) (n = 23) and control individuals who did not have either of the neurological diseases or any other disease that might affect the angiotensin II levels in the CSF (control) (n = 24). Angiotensin II levels in the CSF were 3.79 ± 1.54 pg/ml in the MS group, 5.13 ± 2.27 pg/ml in the IN group and 6.71 ± 2.65 pg/ml in the control group. The angiotensin II levels in the CSF of the MS group were significantly lower than in the control group (p = 0.00057). Angiotensin II concentration in the CSF tended to have a negative correlation with the Kurtzke's Expanded Disability Status Scale scores during MS relapse (p = 0.0847). These findings suggest that reduced levels of intrathecal angiotensin II may be related to the abnormal neural damage and repair processes in MS.

Original languageEnglish
Pages (from-to)557-560
Number of pages4
JournalMultiple Sclerosis
Volume14
Issue number4
DOIs
Publication statusPublished - May 1 2008

Fingerprint

Angiotensin II
Multiple Sclerosis
Cerebrospinal Fluid
Angiotensin Type 2 Receptor
Control Groups
Autoimmune Experimental Encephalomyelitis
Recurrence
Wounds and Injuries
Enzymes

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. / Kawajiri, Masakazu; Mogi, M.; Osoegawa, M.; Matsuoka, T.; Tsukuda, K.; Kohara, K.; Horiuchi, M.; Miki, T.; Kira, Jun-Ichi.

In: Multiple Sclerosis, Vol. 14, No. 4, 01.05.2008, p. 557-560.

Research output: Contribution to journalArticle

Kawajiri, M, Mogi, M, Osoegawa, M, Matsuoka, T, Tsukuda, K, Kohara, K, Horiuchi, M, Miki, T & Kira, J-I 2008, 'Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis', Multiple Sclerosis, vol. 14, no. 4, pp. 557-560. https://doi.org/10.1177/1352458507085760
Kawajiri M, Mogi M, Osoegawa M, Matsuoka T, Tsukuda K, Kohara K et al. Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Multiple Sclerosis. 2008 May 1;14(4):557-560. https://doi.org/10.1177/1352458507085760
Kawajiri, Masakazu ; Mogi, M. ; Osoegawa, M. ; Matsuoka, T. ; Tsukuda, K. ; Kohara, K. ; Horiuchi, M. ; Miki, T. ; Kira, Jun-Ichi. / Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. In: Multiple Sclerosis. 2008 ; Vol. 14, No. 4. pp. 557-560.
@article{fdab218a17ef4282aa60b64f698b69b8,
title = "Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis",
abstract = "We previously demonstrated that angiotensin II acts as a crucial neuroprotective factor after neural injury through angiotensin II type-2 (AT2) receptor signaling. Although the pathway is known to play an important role in the development of experimental autoimmune encephalomyelitis, cerebrospinal fluid (CSF) angiotensin II levels in patients with multiple sclerosis (MS) have never been studied. To clarify the significance of angiotensin II in MS, we assayed angiotensin II concentrations using an established enzyme-linked immunoabsorbent assay in CSF samples from patients with MS (n = 21), patients with inflammatory neuropathies (IN) (n = 23) and control individuals who did not have either of the neurological diseases or any other disease that might affect the angiotensin II levels in the CSF (control) (n = 24). Angiotensin II levels in the CSF were 3.79 ± 1.54 pg/ml in the MS group, 5.13 ± 2.27 pg/ml in the IN group and 6.71 ± 2.65 pg/ml in the control group. The angiotensin II levels in the CSF of the MS group were significantly lower than in the control group (p = 0.00057). Angiotensin II concentration in the CSF tended to have a negative correlation with the Kurtzke's Expanded Disability Status Scale scores during MS relapse (p = 0.0847). These findings suggest that reduced levels of intrathecal angiotensin II may be related to the abnormal neural damage and repair processes in MS.",
author = "Masakazu Kawajiri and M. Mogi and M. Osoegawa and T. Matsuoka and K. Tsukuda and K. Kohara and M. Horiuchi and T. Miki and Jun-Ichi Kira",
year = "2008",
month = "5",
day = "1",
doi = "10.1177/1352458507085760",
language = "English",
volume = "14",
pages = "557--560",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis

AU - Kawajiri, Masakazu

AU - Mogi, M.

AU - Osoegawa, M.

AU - Matsuoka, T.

AU - Tsukuda, K.

AU - Kohara, K.

AU - Horiuchi, M.

AU - Miki, T.

AU - Kira, Jun-Ichi

PY - 2008/5/1

Y1 - 2008/5/1

N2 - We previously demonstrated that angiotensin II acts as a crucial neuroprotective factor after neural injury through angiotensin II type-2 (AT2) receptor signaling. Although the pathway is known to play an important role in the development of experimental autoimmune encephalomyelitis, cerebrospinal fluid (CSF) angiotensin II levels in patients with multiple sclerosis (MS) have never been studied. To clarify the significance of angiotensin II in MS, we assayed angiotensin II concentrations using an established enzyme-linked immunoabsorbent assay in CSF samples from patients with MS (n = 21), patients with inflammatory neuropathies (IN) (n = 23) and control individuals who did not have either of the neurological diseases or any other disease that might affect the angiotensin II levels in the CSF (control) (n = 24). Angiotensin II levels in the CSF were 3.79 ± 1.54 pg/ml in the MS group, 5.13 ± 2.27 pg/ml in the IN group and 6.71 ± 2.65 pg/ml in the control group. The angiotensin II levels in the CSF of the MS group were significantly lower than in the control group (p = 0.00057). Angiotensin II concentration in the CSF tended to have a negative correlation with the Kurtzke's Expanded Disability Status Scale scores during MS relapse (p = 0.0847). These findings suggest that reduced levels of intrathecal angiotensin II may be related to the abnormal neural damage and repair processes in MS.

AB - We previously demonstrated that angiotensin II acts as a crucial neuroprotective factor after neural injury through angiotensin II type-2 (AT2) receptor signaling. Although the pathway is known to play an important role in the development of experimental autoimmune encephalomyelitis, cerebrospinal fluid (CSF) angiotensin II levels in patients with multiple sclerosis (MS) have never been studied. To clarify the significance of angiotensin II in MS, we assayed angiotensin II concentrations using an established enzyme-linked immunoabsorbent assay in CSF samples from patients with MS (n = 21), patients with inflammatory neuropathies (IN) (n = 23) and control individuals who did not have either of the neurological diseases or any other disease that might affect the angiotensin II levels in the CSF (control) (n = 24). Angiotensin II levels in the CSF were 3.79 ± 1.54 pg/ml in the MS group, 5.13 ± 2.27 pg/ml in the IN group and 6.71 ± 2.65 pg/ml in the control group. The angiotensin II levels in the CSF of the MS group were significantly lower than in the control group (p = 0.00057). Angiotensin II concentration in the CSF tended to have a negative correlation with the Kurtzke's Expanded Disability Status Scale scores during MS relapse (p = 0.0847). These findings suggest that reduced levels of intrathecal angiotensin II may be related to the abnormal neural damage and repair processes in MS.

UR - http://www.scopus.com/inward/record.url?scp=46749137551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749137551&partnerID=8YFLogxK

U2 - 10.1177/1352458507085760

DO - 10.1177/1352458507085760

M3 - Article

C2 - 18562510

AN - SCOPUS:46749137551

VL - 14

SP - 557

EP - 560

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 4

ER -